|
Volumn 23, Issue 3, 2012, Pages 507-512
|
A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALDOSTERONE ANTAGONIST;
BIOLOGICAL MARKER;
PLACEBO;
POTASSIUM;
SPIRONOLACTONE;
ADULT;
AGED;
ANALYSIS OF VARIANCE;
ARTICLE;
BLOOD;
CHI SQUARE DISTRIBUTION;
CHRONIC KIDNEY FAILURE;
CLINICAL TRIAL;
CONTINUOUS AMBULATORY PERITONEAL DIALYSIS;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CONVALESCENCE;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
DRUG MONITORING;
ECHOGRAPHY;
FEMALE;
HEART FAILURE;
HEART STROKE VOLUME;
HUMAN;
IRAN;
MALE;
MIDDLE AGED;
PATHOPHYSIOLOGY;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
TIME;
TREATMENT OUTCOME;
ADULT;
AGED;
ALDOSTERONE ANTAGONISTS;
ANALYSIS OF VARIANCE;
BIOLOGICAL MARKERS;
CHI-SQUARE DISTRIBUTION;
DOUBLE-BLIND METHOD;
DRUG MONITORING;
FEMALE;
HEART FAILURE;
HUMANS;
IRAN;
KIDNEY FAILURE, CHRONIC;
MALE;
MIDDLE AGED;
PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY;
PLACEBOS;
POTASSIUM;
PROSPECTIVE STUDIES;
RECOVERY OF FUNCTION;
SPIRONOLACTONE;
STROKE VOLUME;
TIME FACTORS;
TREATMENT OUTCOME;
|
EID: 84862697216
PISSN: 13192442
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (60)
|
References (0)
|